Sky Labs CART: A Cuffless BP Ring With Real Regulatory Approval
Sky Labs' CART ring cleared UK MHRA and EU CE-MDR after 1,700 Korean hospitals and 150,000 prescriptions. What cuffless 24-hour BP monitoring actually requires.
APOE2: The Gene That Supercharges Your Neurons' DNA Repair
Buck Institute research links APOE2 to measurably lower neuronal senescence and stronger DNA repair — the mechanism behind why APOE2 carriers resist Alzheimer's disease.
DEXA Scans Are Not All Equal: Fitnescity's New Clinical Standard
A DEXA scan at one clinic may not be comparable to another. Fitnescity's Clinical Integrity Standard defines what consistent body composition testing requires.
Ultra-Processed Foods Cut Sperm Motility 18% in Just Three Weeks
3 weeks of ultra-processed food cut sperm motility 18% and testosterone 11% in a controlled trial — without eating extra calories. The mechanism matters.
At-Home Finger-Prick Test Hits 86% Accuracy for Alzheimer's
Nature Medicine validated at-home p-tau217 finger-prick sampling at 86% accuracy. Here's what it means for early Alzheimer's detection.
MBX 4291 Monthly GLP-1 Shows 7% Weight Loss at Eight Weeks
MBX 4291 hit 7% weight loss at 8 weeks with a 26-day half-life supporting true once-monthly dosing — and Phase 1 data shows no serious safety signals.
Function Buys SuppCo: What Independent Supplement Testing Really Reveals
Function.health acquires SuppCo to add ISO-verified supplement testing to its 160-test biomarker platform. The backstory: roughly half of top-selling supplements fail their own label claims.
WHOOP Goes Clinical: What On-Demand Doctor Access Means for Your Recovery Data
WHOOP launches live clinician consultations on May 19 — the same day Fitbit rebrands to Google Health. What the parallel moves mean for serious health trackers.
Function Health: The Case for Testing Insulin Before You Need To
Function Health offers 160+ lab tests covering metabolic and hormonal markers that standard care skips — here's what the extra data actually tells you.
Peptide Telehealth in 2026: The GLP-1 Distribution Model Reaches Longevity
LifespanningRx's partner program brings compounded peptide protocols to independent clinicians in 24 hours — the same telehealth model that mainstreamed GLP-1.
Niagen Plus: Why the NAD+ Market Just Went Injectable
Niagen Bioscience's $299 at-home injection kit delivers pharmaceutical-grade NR subcutaneously — bypassing gut metabolism. What the biohacking shift to injectables signals.
Peter Attia AMA #84: Family History, NAD Skepticism, and Dementia Risk
Peter Attia AMA #84: why family health history outperforms genetic testing, his stance on NAD supplements, and minimum effective strength training dose.
EL-22: The Engineered Probiotic Targeting the Muscle Loss That GLP-1 Drugs Leave Behind
NorthStrive Biosciences has patented EL-22, a myostatin-inhibiting probiotic designed to preserve lean muscle during GLP-1-driven weight loss — addressing one of the category's most significant side effects.
Rapamycin + Exercise: Why the First Real Trial Disappointed
Rapamycin may blunt exercise gains in older adults. Peter Attia: this trial is underpowered—but the HbA1c signal is real.
Lipid-Lowering Pharmacotherapy: The Decision That Actually Determines Outcomes
92 million Americans take statins, but which lipid-lowering drug you take matters less than matching it to your dominant cholesterol pathway. Here's the framework.
Muscle as Medicine: Why Strength Is the Missing Variable in Longevity
When 40% of weight-loss drug results come from muscle, health outcomes worsen. Here's why strength — not scale weight — is the longevity lever that determines outcomes.
ŌURA's Acquisition Strategy: Building a Health AI Stack From Ring to Medical Records
Oura has acquired five companies since 2023 — gesture control, metabolic data, performance analytics, and now clinical records across 800+ healthcare systems. The pattern reveals a deliberate platform strategy.
Inbrain's Graphene Brain Interface: First Human Trial Results Signal a New Class of Neural Device
Inbrain's graphene cortical interface completed its first 8-patient human trial with no device-related adverse events — a safety milestone for a neural recording technology designed to be thinner and more biocompatible than conventional silicon.
Osteoboost's FDA-Cleared Wearable Uses Vibration to Slow Bone Loss
Osteoboost's prescription wearable delivers high-frequency vibration to the lumbar spine to slow bone density loss — FDA cleared, 82% adherence in trials, and backed by $8M to crack insurance coverage.
Your Immune System Can Now Have a Digital Twin — Here's What That Means
A Zurich clinic and Barcelona AI firm just launched the first commercial immune digital twin platform. It's early-stage, but the model it represents is where preventive health is heading.
60% of Workers Rank Health Access First. Employers Are Behind.
A new UK survey finds 60% of workers rank health insurance above all other benefits — a signal that healthspan is reshaping what employees expect from employers.
Hone Health + BodySpec: Clinical DEXA Inside Your Longevity OS
Hone Health and BodySpec integrate clinical DEXA scans into a longevity OS, moving bone composition data from reactive diagnosis to preventive care.
Peptides: Peter Attia Separates the Science From the Hype in AMA #83
BPC-157 has three small studies with no control groups. TB-500 and GHK-Cu have animal data only. Peter Attia's AMA #83 maps what the evidence actually shows — and why the regulatory picture is shifting fast.
Your Workout May Train Your Kids Too: Peter Attia's April 2026 Research Roundup
Paternal exercise reprograms sperm microRNAs that improve offspring endurance capacity. Plus: autonomic nervous system imbalance as a unifying theory of aging. Four studies from Attia's April roundup.